Protective behaviors against SARS-CoV-2 infection: a cohort study
DOI:
https://doi.org/10.11606/issn.1679-9836.v102i5e-203045Keywords:
COVID-19, SARS-Cov-2, Preventives measures, MedicinesAbstract
INTRODUCTION: We designed a prospective study aiming to assess factors (adherence to social distancing, use of PPE, etc.) that could be determinants in the development of COVID-19 that may subsidize the development of effective health strategies to combat the infection in the municipality of Passos - Minas Gerais, Brazil, whether in the hospital or non-hospital settings. METHODS: This is a longitudinal cohort study where 343 individuals from the population were included and randomly selected by clusters. The selected individuals answered a questionnaire related to clinical characteristics, preventive measures, comorbidities, and medication use. A rapid test was performed on the individuals to detect IgG and IgM antibodies. The average follow-up period was six months, and during the follow-up, telephone contact was maintained every two weeks. At the end of the follow-up, a new serological test was performed, and the risk associated with risk factors and disease incidence was calculated. RESULTS: We found that 27.3% of patients who became infected during follow-up were using ivermectin and hydroxychloroquine as a means of prevention, while in non-infected patients, 11.3% used these drugs. (p = 0.024). For patients who had the disease during follow-up, 21.2% reported respecting social isolation, 27.3% reported leaving for work, and 42.14% reported having attended hospital environments (p = 0.004). Among the participants who had the infection, 12.1% reported contact only with family members, 9.1% with family members and co-workers, and 75.8% with health professionals (p = 0.001). CONCLUSIONS: This study provided epidemiological data on patients infected with COVID-19, which can contribute to the health system's establishment of preventive measures.
Downloads
References
Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress. 2020;4(4):66-75. doi: 10.15698/cst2020.04.216
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7
MacIntyre CR, Chughtai AA. A rapid systematic review of the efficacy of face masks and respirators against coronaviruses and other respiratory transmissible viruses for the community, healthcare workers and sick patients. Int J Nurs Stud. 2020;108:103629. doi: 10.1016/j.ijnurstu.2020.103629
Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-87. doi: 10.1016/S0140-6736(20)31142-9
Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021;3(1):e19-e27. doi: 10.1016/S2665-9913(20)30378-7
Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure sars-cov-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med. 2021;181(2):195-202. doi: 10.1001/jamainternmed.2020.6319
Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. Clin Infect Dis. 2021;72(11):e835-e843.2020 Oct. doi: 10.1093/cid/ciaa1571
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787
Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021;32:100720. doi: 10.1016/j.eclinm.2020.100720
Veit O, Beck B, Steuerwald M, Hatz C. First case of ivermectin-induced severe hepatitis. Trans R Soc Trop Med Hyg. 2006;100(8):795-7. doi: 10.1016/j.trstmh.2006.02.003
Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. Clin Infect Dis. 2021;73(2):328–31. doi: 10.1093/cid/ciaa1150
Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020 11;11(1):5761. doi: 10.1038/s41467-020-19623-x
Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020;383(16):1522-34. doi: 10.1056/NEJMoa2020283
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323(13):1239-42. doi: 10.1001/jama.2020.2648
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71(15):896-7. doi: 10.1093/cid/ciaa415
Bhasin A, Nam H, Yeh C, Lee J, Liebovitz D, Achenbach C. Is BMI higher in younger patients with COVID-19? Association Between BMI and COVID-19 Hospitalization by Age. Obesity (Silver Spring). 2020;28(10):1811-4. doi: 10.1002/oby.22947
The Lancet. COVID-19: protecting health-care workers. Lancet. 2020;395(10228):922. doi: 10.1016/S0140-6736(20)30644-9
Ferioli M, Cisternino C, Leo V, Pisani L, Palange P, Nava S. Protecting healthcare workers from SARS-CoV-2 infection: practical indications. Eur Respir Rev. 2020;29(155). doi: 10.1183/16000617.0068-2020
Organization WH. Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages 2020.
Ribeiro, Peixoto A. Saúde e segurança de profissionais de saúde no atendimento a pacientes no contexto da pandemia de Covid-19. Rev Bras Saúde Ocup. 2020;45:e-25. https://doi.org/10.1590/2317-6369000013920
Sanitária ANdV. Orientações Gerais – Máscaras faciais de uso não profissional 2020. www.anvisa.gov.br.
Health W, Organization. Advice on the use of masks in the context of COVID-19: interim guidance. Geneva2020. WHO/2019-nCov/IPC_Masks/2020.3
Li T, Liu Y, Li M, Qian X, Dai SY. Mask or no mask for COVID-19: A public health and market study. PLoS One. 2020;15(8):e0237691. doi: 10.1371/journal.pone.0237691
Alves JR, Salomé GM, Miranda FD. Application for coping with COVID-19 by health professionals in home care. Acta Paul Enferm. 2022;35:eAPE01436. doi: 10.37689/acta-ape/2022AO014366
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Aguimar Xavier de Carvalho Filho, Maria Julia Nascimento Lemos, Marina Lima Ribeiro, José Auri Vilela Lemos Queiros, Maria Clara Morais Melo, Nubia Taveira Carvalhaes Assad, Isabela Ranieri Silos, Bruna Andrade Pereira, Alexia Floriano Rodrigues da Silva, Ghaspar Gomes de Oliveira Alves Francisco, Caroline Brandão Chiovatto, Ruan Pimenta, Katia Ramos Moreira Leite, Vanessa Luzia Queiroz, Elexandra Helena Bernardes, Alexandre Beraldo Ordones, Sabrina Thalita dos Reis Faria

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.